Literature DB >> 7505187

Octreotide in relieving gastrointestinal symptoms due to bowel obstruction.

S Mercadante1, E Spoldi, A Caraceni, S Maddaloni, M T Simonetti.   

Abstract

Gastrointestinal obstruction is a common problem in advanced malignant disease, but its management remains controversial. In those patients for whom surgery is not appropriate, medical intervention is the only remaining option. We present a series of 14 patients with intestinal obstruction who were managed with subcutaneous injections of octreotide, a somatostatin analogue which reduces the volume of gastrointestinal secretions. Good control of vomiting was achieved in 12 patients, and no major side effects were observed. Octreotide would appear to be a useful drug in this clinical situation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505187     DOI: 10.1177/026921639300700406

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  11 in total

Review 1.  [Pharmacological treatment of malignant bowel obstruction in severely ill and dying patients : a systematic literature review].

Authors:  C Klein; S Stiel; J Bükki; C Ostgathe
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

2.  [Palliative symptom control in malignant bowel obstruction due to advanced ovarian cancer].

Authors:  Kurt Alker; Franz Harnoncourt
Journal:  Wien Med Wochenschr       Date:  2006-05

3.  Why not octreotide?

Authors:  S Mercadante
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

4.  Bowel obstruction in home-care cancer patients: 4 years experience.

Authors:  S Mercadante
Journal:  Support Care Cancer       Date:  1995-05       Impact factor: 3.603

5.  Octreotide acetate enables the administration of chemoradiotherapy, including the oral anticancer drug S-1, in gastric cancer patients with malignant gastrointestinal obstruction.

Authors:  Tsunehiro Takahashi; Yoshiro Saikawa; Takahiro Igarashi; Shinichi Tsuwano; Koshi Kumagai; Rieko Nakamura; Takashi Ooyama; Norihito Wada; Hiroya Takeuchi; Hiromasa Takaishi; Yuko Kitagawa
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

6.  [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review].

Authors:  G Benze; A Geyer; B Alt-Epping; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

7.  Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital.

Authors:  Michael Hwang; Rosene Pirrello; Minya Pu; Karen Messer; Eric Roeland
Journal:  Support Care Cancer       Date:  2013-06-04       Impact factor: 3.603

8.  Conservative treatment of early postoperative small bowel obstruction with obliterative peritonitis.

Authors:  Jian-Feng Gong; Wei-Ming Zhu; Wen-Kui Yu; Ning Li; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

9.  Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction.

Authors:  Robert J Litwin; Alda L Tam; Rahul A Sheth; Steven M Yevich; Johanna L Chan; Amir A Jazaeri; Josiah K Halm; Sanjay Gupta; Steven Y Huang
Journal:  Abdom Radiol (NY)       Date:  2021-05-17

10.  Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.

Authors:  Xingang Peng; Peige Wang; Shikuan Li; Guangyong Zhang; Sanyuan Hu
Journal:  World J Surg Oncol       Date:  2015-02-15       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.